Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 9072 in acute exacerbation of schizophrenia
NCT01469039Phase 3Completed
- Sponsor
- Alkermes
- Start
- Dec 2011
- Primary completion
- Jan 2014
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of aripiprazole lauroxil in schizophrenia, sponsored by Alkermes. Started Dec 2011; status: completed.
02
Drugs
aripiprazole lauroxil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01469039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01469039.